DAILY-LUMA 队列中 2 年 Lumasiran 真实世界数据
DAILY-LUMA 是法国官方要求的 quasi-exhaustive 上市后研究,纳入 38 例未参加企业试验且使用 lumasiran 至少 2 年的原发性高草酸尿症 1 型患者。DAILY-A 和 DAILY-B 患者尿草酸/肌酐比值下降,eGFR 稳定,肾钙质沉着症严重程度和结石数量减少,保守治疗逐步减量。DAILY-C 患者数少结果不确定,但年长患者血浆草酸水平变化与既往数据相似,耐受性良好。
要点
- DAILY-A/B 患者使用 lumasiran 2 年后尿草酸/肌酐比值下降,eGFR 稳定。
- 肾钙质沉着症严重程度和结石数量减少,夜间补水和胃造瘘管需求逐步减少。
- DAILY-C 患者数少结果不确定,但年长患者血浆草酸变化与既往数据相似。
核心结论
- DAILY-LUMA 是真实世界中最大的 lumasiran 队列,证实其 2 年安全有效。
研究设计与样本
- 法国官方要求的 quasi-exhaustive 回顾性和前瞻性上市后研究,计划随访 5 年,要求纳入至少 90% 患者。
- 纳入 38 例未参加企业试验且使用 lumasiran 至少 2 年的患者:DAILY-A 22 例(eGFR>45 ml/min/1.73m2,年龄≥6 岁),DAILY-B 6 例(eGFR>45 ml/min/1.73m2,年龄<6 岁),DAILY-C 10 例(所有年龄,eGFR<45 ml/min/1.73m2,其中 6 例透析)。
主要发现
- DAILY-A 和 DAILY-B 中观察到尿草酸/肌酐比值下降、eGFR 稳定、肾钙质沉着症严重程度和结石数量减少,保守治疗逐步减量。
- 夜间补水和胃造瘘管使用患者比例随时间下降,可能反映生活质量改善。
- DAILY-C 患者数少(2 例腹膜透析、3 例婴儿型草酸症),结果较不确定;但年长患者血浆草酸水平变化与既往发表数据相似。
- 耐受性良好,无严重副作用;主要不良事件为注射部位反应、腹痛和头痛。
临床怎么用
- 对于 PH1 患者,lumasiran 治疗 2 年可降低尿草酸、稳定肾功能并减轻结石负荷,支持真实世界中使用。
- 治疗过程中可逐步减少保守治疗措施如夜间补水和胃造瘘管,但需结合患者具体情况。
- 在 eGFR<45 ml/min/1.73m2 或透析患者中数据有限,需个体化评估。
局限性
- DAILY-C 患者数少,尤其腹膜透析和婴儿型草酸症患者,结果不具结论性。
- 为非随机、观察性研究,存在混杂因素可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Lumasiran is a drug used in RNA-interference (RNAi) therapy for primary hyperoxaluria type 1 (PH1). Data on its efficacy and safety mainly come from industry-sponsored trials. METHODS: For postmarketing follow-up, French authorities requested a quasi-exhaustive retrospective and prospective study over 5 years for patients receiving lumasiran, requiring the inclusion of at least 90% of patients, named as the DAILY-LUMA cohort (NCT06225882). Here, we analyzed data from all patients who were not previously included in the industry-sponsored trials and had received lumasiran for at least 2 years. RESULTS: We included 38 patients, 22 from DAILY-A (i.e., estimated glomerular filtration rate (eGFR) > 45 ml/min per 1.73 m2, age ≥ 6 years), 6 from DAILY-B (i.e., eGFR > 45 ml/min per 1.73 m2, age < 6 years), and 10 from DAILY-C (i.e., all ages, eGFR < 45 ml/min per 1.73 m2, 6 on dialysis). In DAILY-A and DAILY-B, decreased urinary oxalate-to-creatinine (UOx/creat) ratio, stable eGFR, and decrease in both nephrocalcinosis severity and stone numbers were observed, with a progressive tapering of conservative therapies. The decreased proportion of patients with nocturnal hydration and G-tubes overtime likely reflects improved quality of life. With a low number of patients - 2 patients on peritoneal dialysis and 3 patients with infantile oxalosis - the results are less conclusive for DAILY-C; however, in older patients, change in plasma oxalate (POx) levels is similar to previously published data. Tolerance was good with no severe side effects; injection site reactions, abdominal pain, and headaches were the main adverse events. CONCLUSION: DAILY-LUMA is the largest cohort of patients receiving lumasiran in real life, confirming its safety and efficacy at 2 years.
引用
- Sellier-Leclerc AL, Cloarec M, Knebelmann B, et al. Real-Life Data of 2-Year Lumasiran Use in the DAILY-LUMA Cohort. Kidney Int Rep. 2024. PMID: 40303203. doi:10.1016/j.ekir.2024.12.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。